MARKET

CGIX

CGIX

CANCER GENETICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.980
-0.020
-0.67%
Closed 16:00 08/12 EDT
OPEN
2.970
PREV CLOSE
3.000
HIGH
3.060
LOW
2.960
VOLUME
20.42K
TURNOVER
--
52 WEEK HIGH
9.50
52 WEEK LOW
1.920
MARKET CAP
6.74M
P/E (TTM)
-1.0015
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CGIX stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

CGIX News

More
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
GlobeNewswire · 06/24 22:30
Cancer Genetics Q1 EPS $(0.56) Up From $(1.06) YoY, Sales $1.40M Down From $1.80M YoY
Cancer Genetics (NASDAQ:CGIX) reported quarterly losses of $(0.56) per share. This is a 47.17 percent increase over losses of $(1.06) per share from the same period last year. The company reported $1.40 million in sales
Benzinga · 06/24 21:31
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
GlobeNewswire · 06/01 13:00
Cancer Genetics Q1 EPS $(0.14) Up From $(0.90) YoY, Sales $1.90M Down From $6.84M YoY
Cancer Genetics (NASDAQ:CGIX) reported quarterly losses of $(0.14) per share. This is a 84.44 percent increase over losses of $(0.90) per share from the same period last year. The company reported $1.90 million in sales
Benzinga · 06/01 12:06
IPO Update: Lantern Pharma Readies $25 Million IPO
Seeking Alpha - Article · 05/12 17:51
Those Who Purchased Cancer Genetics (NASDAQ:CGIX) Shares Five Years Ago Have A 99% Loss To Show For It
Simply Wall St. · 05/12 11:37
Lantern Pharma Starts U.S. IPO Process
Seeking Alpha - Article · 04/17 20:19
CIM, GLNG, TWO and LADR among midday movers
Seeking Alpha - Article · 04/07 16:41

Industry

Healthcare Facilities & Services
+0.30%
Healthcare Providers & Services
+1.28%

Hot Stocks

Symbol
Price
%Change

About CGIX

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.
More

Webull offers kinds of Cancer Genetics Inc stock information, including NASDAQ:CGIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGIX stock methods without spending real money on the virtual paper trading platform.